IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CAVALIERI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.420
NA - Nord America 2.091
AS - Asia 1.649
SA - Sud America 48
OC - Oceania 29
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.257
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 2.809
US - Stati Uniti d'America 2.031
CN - Cina 654
IT - Italia 493
GB - Regno Unito 334
JP - Giappone 215
SG - Singapore 207
SE - Svezia 186
IN - India 179
FR - Francia 109
IE - Irlanda 102
RU - Federazione Russa 95
TW - Taiwan 88
HK - Hong Kong 87
ID - Indonesia 61
DK - Danimarca 52
ES - Italia 52
CA - Canada 50
KR - Corea 39
CH - Svizzera 30
AU - Australia 27
VN - Vietnam 26
BR - Brasile 24
PH - Filippine 24
NL - Olanda 23
BE - Belgio 19
FI - Finlandia 19
TR - Turchia 17
TH - Thailandia 16
UA - Ucraina 13
AR - Argentina 12
GR - Grecia 11
PL - Polonia 11
RO - Romania 10
PT - Portogallo 9
NO - Norvegia 8
IR - Iran 7
MX - Messico 7
RS - Serbia 7
SC - Seychelles 7
AT - Austria 6
IL - Israele 6
MY - Malesia 6
EC - Ecuador 5
CZ - Repubblica Ceca 4
HU - Ungheria 4
MA - Marocco 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
EG - Egitto 3
AP - ???statistics.table.value.countryCode.AP??? 2
BY - Bielorussia 2
HR - Croazia 2
KZ - Kazakistan 2
MO - Macao, regione amministrativa speciale della Cina 2
PA - Panama 2
PE - Perù 2
PK - Pakistan 2
TN - Tunisia 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
BS - Bahamas 1
CL - Cile 1
CO - Colombia 1
EE - Estonia 1
FJ - Figi 1
IS - Islanda 1
KE - Kenya 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
SA - Arabia Saudita 1
SI - Slovenia 1
VA - Santa Sede (Città del Vaticano) 1
Totale 8.257
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 2.618
Chandler 273
Southend 260
Fairfield 203
Milan 163
Singapore 139
Redwood City 117
Ashburn 111
Princeton 111
Dublin 101
Seattle 85
Beijing 82
Tokyo 79
Wilmington 79
Woodbridge 79
Houston 71
Hong Kong 65
Ann Arbor 63
Shanghai 52
Cambridge 50
Taipei 49
Jakarta 48
Bengaluru 43
Dearborn 42
Nanjing 39
Des Moines 38
Berlin 35
Grafing 35
Rome 31
Santa Clara 28
Hyderabad 27
Ottawa 26
Hanover 24
Seoul 23
Madrid 22
Boardman 21
Shenyang 21
Chicago 20
Jinan 19
London 19
Guangzhou 17
Helsinki 17
Hefei 16
Nanchang 15
New York 15
Wuhan 14
Changsha 13
Dong Ket 13
Paris 13
Bangkok 12
Hangzhou 12
Hebei 12
Phoenix 12
Toronto 12
Barcelona 11
Chengdu 11
San Diego 11
Zhengzhou 11
Bologna 10
Central District 10
Los Angeles 10
Tianjin 10
Brussels 9
Fremont 9
Zurich 9
Asahicho 8
Brescia 8
Buffalo 8
Florence 8
Fuzhou 8
Jiaxing 8
Kent 8
Madison 8
Nuremberg 8
Pavia 8
Chongqing 7
Cleveland 7
Dallas 7
Medford 7
Miaoli 7
Moscow 7
Mumbai 7
Silver Spring 7
Sydney 7
São Paulo 7
Changchun 6
Falls Church 6
Gurgaon 6
Istanbul 6
Melbourne 6
Tainan City 6
Verona 6
Washington 6
Yongin-si 6
Ankara 5
Campinas 5
Kyoto 5
Mahé 5
Nagoya 5
Ningbo 5
Totale 5.949
Salva come PNG Salva come JPEG
Nome #
Lenvatinib-induced renal failure : two first-time case reports and review of literature 931
Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis 482
Clinical implications for pro-GRP in small cell lung cancer. A single center experience 344
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study 309
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 283
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? 253
Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients 190
An old but still unanswered question in recurrent or metastatic salivary duct carcinoma 142
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol 138
Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer 134
Identification of potentially druggable molecular alterations in skin adnexal malignancies 133
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract 123
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 121
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents 119
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer 117
Modelling radiation‐induced salivary dysfunction during IMRT and chemotherapy for nasopharyngeal cancer patients 117
Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report 117
Immuno-oncology in head and neck squamous cell cancers : News from clinical trials, emerging predictive factors and unmet needs 113
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) 108
Locally advanced epithelial sinonasal tumors: The impact of multimodal approach 108
Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers 105
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors 105
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: case series and large-scale pharmacovigilance analysis 101
Biological Rationale and Clinical Evidence of Carbon Ion Radiation Therapy for Adenoid Cystic Carcinoma: A Narrative Review 99
Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting : the INT Milan experience 96
Baseline mri-radiomics can predict overall survival in non-endemic ebv-related nasopharyngeal carcinoma patients 94
Bleeding complications in patients with squamous cell carcinoma of the head and neck 90
The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers 89
Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus-Positive Oropharyngeal Carcinoma 89
Uncommon somatic mutations in metastatic NUT midline carcinoma 88
Mining of self-organizing map gene-expression portraits reveals prognostic stratification of HPV-positive head and neck squamous cell carcinoma 84
Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project 84
Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy 83
Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era 83
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma 81
Induction chemotherapy is the best timekeeper in nasopharyngeal carcinoma 81
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer 80
Targeted-gene sequencing to catch triple negative breast cancer heterogeneity before and after neoadjuvant chemotherapy 80
Particle beam therapy tolerance and outcome on patients with autoimmune diseases : A single institution matched case–control study 79
Quality Assessment in Supportive Care in Head and Neck Cancer 79
Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting 78
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients 77
HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients 76
Fatigue, a major still underestimated issue 75
Current status and perspectives in immunotherapy for metastatic melanoma 75
A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images 74
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 73
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic 73
Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies 71
Management of loco-regionally advanced squamous laryngeal cancer in elderly patients 71
Methodology and technology for the development of a prognostic MRI-based radiomic model for the outcome of head and neck cancer patients 70
Prognostic radiomic signature for head and neck cancer: Development and validation on a multi-centric MRI dataset 69
Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials 68
Rare thyroid malignancies in Europe : Data from the information network on rare cancers in Europe (RARECAREnet) 68
Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands 67
Radiation-Induced Oropharyngeal Squamous Cell Carcinoma: Case Report and Review of the Literature 65
Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities 65
Which future for de-intensified treatments in HPV-related oropharyngeal carcinoma? 62
A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma 60
Integrating population data in a computerized Decision Support System for Head and Neck Cancer 58
Quality of life in head and neck cancer survivors: the Big Data for Quality of Life study 57
A randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy of Aqualief™ mucoadhesive tablets in head and neck cancer patients who developed radiation-induced xerostomia 56
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life 54
Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case 53
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/ metastatic head and neck squamous cell carcinoma treated with nivolumab 52
Erratum: Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy (PLoS ONE (2020) 15:5 (e0232639) DOI: 10.1371/journal.pone.0232639) 52
Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial 51
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure 49
HeNeCOn: An ontology for integrative research in Head and Neck cancer 49
Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series 49
Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma 49
NUT carcinoma of the submandibular gland: A case report 48
Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report 48
MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures 45
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience 44
Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib 44
Editorial: Diagnosis, epidemiology and treatment of salivary gland carcinomas 44
Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients 44
HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19 40
Smartphone-Based Strategy for Quality-of-Life Monitoring in Head and Neck Cancer Survivors 35
Next generation platinum salt in nasopharygeal carcinoma 34
Unusual skin carcinomas induced by BRAF inhibitor for metastatic melanoma: A case report 32
Immunotherapy for recurrent/metastatic head and neck cancer 31
An Ontology for Quality of Life Modeling in Head and Neck Cancer 29
A Clinically Translatable Immune-based Classification of HPV-associated Head and Neck Cancer with Implications for Biomarker-Driven Treatment Deintensification and Immunotherapy 7
Management of patients with skin adnexal carcinomas 2
MRI radiomics in head and neck cancer from reproducibility to combined approaches 1
Claudin-1 in Head and Neck Squamous Cell Carcinoma 1
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? 1
Totale 8.648
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.253
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.253
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020855 0 0 62 115 75 102 91 65 126 89 54 76
2020/2021945 69 47 61 39 63 140 132 83 109 65 44 93
2021/20221.086 75 62 55 51 129 75 56 116 111 97 69 190
2022/20231.207 161 104 123 106 98 201 39 63 109 69 95 39
2023/20242.828 51 84 75 58 193 103 382 295 230 379 493 485
2024/20251.228 438 500 290 0 0 0 0 0 0 0 0 0
Totale 8.648